The issue is about mounting numbers of patients with gastritis and pancreatitis after use of GLP-1 agonists and what happens next with those patients, as they obviously need to stop GLP-1 agonists?!
Novo Nordisk, the maker of Ozempic, is named as a defendant in the multidistrict litigation for people claiming blindness from GLP-1 drugs (MDL No
For instance, nZVI assists in reducing toxic As(V) into less harmful forms of As(III), which can be precipitated and removed during the process of cleaning water contaminated with arsenic
A consultation with our medical team and comprehensive digestive health assessment are required to determine if this therapy is appropriate for you.
While it may cause temporary changes in heart rate and rhythm, these effects are generally mild and transient
However, with the right approach, its possible to minimize this risk